winter
number
viral
respiratori
tract
infect
germani
highest
observ
past
decad
infect
respiratori
virus
common
caus
usual
mild
respiratori
ill
age
group
immunosuppress
adult
elderli
person
underli
chronic
condit
howev
increas
risk
sever
cours
diseas
hematopoiet
stem
cell
recipi
respiratori
virus
caus
higher
rate
lower
respiratori
tract
diseas
associ
higher
mortal
rate
patient
hematolog
disord
present
respiratori
symptom
screen
influenza
viru
parainfluenza
viru
respiratori
syncyti
viru
rsv
recommend
although
vaccin
season
pandem
influenza
avail
vaccin
parainfluenza
rsv
still
develop
howev
effect
vaccin
immunosuppress
patient
limit
major
pathogen
caus
sever
lower
respiratori
tract
diseas
immunocompromis
adult
rsv
high
prioriti
vaccin
develop
rsv
infect
partial
induc
protect
immun
repeat
infect
occur
childhood
throughout
life
strain
variat
respiratori
virus
thought
contribut
abil
caus
frequent
reinfect
attach
protein
rsv
abl
accommod
chang
emerg
new
variant
sequenc
hypervari
gene
region
wide
use
subdivid
parainfluenza
rsv
genotyp
facilit
differenti
viru
isol
influenza
virus
highli
variabl
character
continu
genet
antigen
drift
accumul
mutat
especi
antigen
site
hemagglutinin
caus
emerg
new
drift
variant
cocircul
differ
group
lineag
viral
shed
studi
provid
fundament
inform
natur
cours
respiratori
viru
infect
relat
clinic
ill
implement
effect
prevent
strategi
influenza
gener
selflimit
infect
system
respiratori
symptom
usual
resolv
within
day
patient
viral
clearanc
respiratori
tract
usual
occur
day
howev
immunocompromis
patient
respiratori
virus
tend
persist
longer
due
constrain
immun
respons
therefor
also
spread
easili
lower
respiratori
tract
prolong
influenza
rsv
viral
shed
previous
describ
immunocompromis
patient
similar
result
observ
rhinoviru
coronaviru
howev
limit
inform
regard
molecular
epidemiolog
respiratori
virus
immunocompromis
adult
combin
preval
durat
clinic
impact
viral
shed
studi
retrospect
investig
patient
respiratori
tract
infect
hematolog
transplant
unit
univers
hospit
heidelberg
decemb
may
perform
molecular
character
influenza
viru
parainfluenza
viru
rsv
investig
genet
divers
pattern
cocircul
subtyp
genotyp
furthermor
assess
preval
durat
clinic
impact
prolong
viral
shed
immunocompromis
adult
heidelberg
univers
hospit
tertiari
referr
center
depart
hematolog
compris
four
inpati
ward
adult
ward
normal
highdos
chemotherapi
one
intermedi
care
unit
one
transplant
well
sever
outpati
clinic
day
hospit
chemotherapi
outpati
basi
administ
patient
treat
suffer
malign
lymphoma
multipl
myeloma
acut
leukemia
year
autolog
allogen
transplant
perform
major
allogen
transplant
patient
receiv
peripher
blood
stem
cell
reduc
condit
regimen
part
standard
oper
procedur
order
inform
infect
control
measur
autumn
spring
hematolog
patient
test
develop
respiratori
symptom
infect
influenza
viru
parainfluenza
viru
rsv
standard
screen
summer
month
patient
sever
otherwis
explic
symptom
test
due
lower
preval
respiratori
viru
infect
season
significantli
increas
number
respiratori
infect
standard
screen
escal
februari
subsequ
patient
screen
infect
influenza
viru
parainfluenza
viru
rsv
admiss
one
ward
regardless
respiratori
symptom
well
test
respiratori
symptom
develop
intensifi
screen
addit
screen
commun
acquir
virus
rhino
adeno
coronaviru
perform
patient
proven
viral
infect
retest
clearanc
viru
sever
patient
lost
followup
regard
viral
shed
furthermor
symptomat
patient
isol
await
laboratori
result
infect
patient
isol
singl
room
isol
cohort
sampl
process
within
two
hour
afterward
kept
frozen
analysi
perform
nasopharyng
sampl
via
revers
transcript
polymeras
chain
reaction
rtpcr
case
respiratori
tract
infect
base
laboratoryconfirm
infect
influenza
viru
parainfluenza
viru
rsv
present
without
respiratori
symptom
urti
defin
presenc
respiratori
symptom
eg
cough
sneez
without
sign
lower
respiratori
tract
diseas
lrti
defin
presenc
respiratori
symptom
plu
radiograph
chest
xray
chest
ct
scan
sign
lower
respiratori
tract
diseas
sever
lrti
defin
lrti
plu
requir
treatment
intens
care
unit
death
nosocomi
infect
defin
viru
detect
day
seven
later
admiss
ward
remaind
defin
communityacquir
infect
howev
communityacquir
case
previous
treat
day
hospit
patient
record
inform
anonym
deidentifi
prior
analysi
ethic
approv
obtain
ethic
committe
univers
heidelberg
purpos
studi
nasopharyng
swab
inpati
outpati
screen
respiratori
virus
influenza
parainfluenza
rsv
winter
season
retrospect
analys
lrti
patient
addit
bronchoalveolar
lavag
bal
sampl
avail
readili
avail
medic
record
retrospect
review
patient
obtain
basic
characterist
clinic
laboratori
data
rna
extract
respiratori
specimen
use
viral
rna
mini
kit
qiagen
hilden
germani
accord
manufactur
protocol
revers
transcript
amplif
detect
viral
rna
perform
influenza
parainfluenza
rsv
realtim
rtpcr
kit
altona
diagnost
hamburg
germani
instrument
ii
roch
mannheim
germani
accord
manufactur
instruct
assay
distinguish
influenza
b
rsv
rsv
b
realstar
parainfluenza
rtpcr
kit
differenti
parainfluenza
viru
type
type
therefor
ftd
respiratori
pathogen
kit
fast
track
diagnost
luxembourg
use
type
sampl
posit
parainfluenza
viru
rna
extract
rna
revers
transcrib
use
random
hexam
primer
subsequ
influenza
viru
hemagglutinin
ha
gene
parainfluenza
viru
f
fusion
gene
second
variabl
region
rsv
g
attach
gene
amplifi
cdna
primer
sequenc
amplif
influenza
viru
ha
gene
avail
request
parainfluenza
viru
primer
tgtattgcttgatctgttggtc
use
rsv
primer
describ
previous
result
pcr
product
sequenc
complet
direct
use
big
dye
termin
chemistri
version
instrument
prism
appli
biosystem
darmstadt
germani
overlap
sequenc
assembl
use
seqman
ii
softwar
lasergen
packag
dnastar
madison
usa
multipl
align
influenza
viru
parainfluenza
viru
rsv
nucleotid
sequenc
carri
mega
softwar
version
phylogenet
tree
construct
mega
use
maximumlikelihood
method
tamuranei
algorithm
influenza
viru
phylogenet
analysi
mega
version
neighbor
join
method
kimura
use
repres
refer
sequenc
influenza
parainfluenza
rsv
genotyp
obtain
genbank
http
wwwncbinlmnihgov
gisaid
global
initi
share
influenza
data
wwwgisaidorg
sequenc
repres
influenza
virus
circul
germani
provid
nation
refer
centr
influenza
includ
phylogenet
analysi
statist
signific
tree
topolog
assess
bootstrap
replic
nucleotid
sequenc
retriev
studi
deposit
genbank
access
number
followup
shed
rsvinfect
patient
conduct
ward
well
outpati
facil
analysi
durat
shed
perform
among
case
sampl
avail
least
two
consecut
week
total
durat
viral
shed
given
infect
calcul
first
posit
final
posit
sampl
allow
four
week
one
neg
sampl
two
consecut
posit
sampl
previous
infect
patient
consid
clear
infect
hesh
asymptomat
two
nasopharyng
sampl
taken
week
apart
test
neg
use
stata
version
stata
corp
colleg
station
tx
usa
statist
analys
fisher
exact
test
appli
univari
analys
logist
regress
model
use
multivari
analys
novemb
decemb
sporad
case
patient
respiratori
viru
infect
detect
pcr
escal
screen
patient
admit
perform
start
week
week
signific
increas
infect
patient
observ
total
number
patient
admit
reason
one
four
hematolog
ward
femal
male
novemb
januari
femal
male
februari
april
novemb
april
total
patient
hematolog
disord
test
presenc
influenza
viru
parainfluenza
viru
rsv
patient
found
infect
patient
influenza
viru
patient
parainfluenza
viru
patient
rsv
six
patient
coinfect
influenza
virusrsv
n
parainfluenza
virusrsv
n
accord
case
definit
influenza
infect
parainfluenza
infect
rsv
infect
communityacquir
epidemiolog
curv
respiratori
infect
shown
fig
standard
infect
control
measur
includ
isol
patient
test
posit
one
respiratori
virus
two
consecut
neg
swab
obtain
cohort
isol
patient
infect
viru
possibl
contact
patient
isol
neg
swab
obtain
end
estim
incub
period
mask
worn
patient
room
transplant
unit
intermedi
care
ward
well
contact
infect
patient
rigor
hand
hygien
implement
period
intensifi
screen
infect
control
measur
intensifi
isol
newli
admit
patient
well
patient
develop
respiratori
symptom
neg
swab
obtain
number
visitor
allow
reduc
two
visitor
per
person
children
age
twelv
longer
admit
ward
mask
obligatori
ward
neither
visitor
medic
nurs
staff
screen
presenc
respiratori
virus
howev
visitor
respiratori
symptom
admiss
ward
medic
nurs
staff
experienc
respiratori
symptom
discourag
direct
patient
contact
mean
age
infect
patient
year
rang
year
male
femal
ratio
distribut
underli
hematolog
disord
similar
overal
patient
popul
depart
hematolog
major
infect
patient
n
underw
stem
cell
transplant
autolog
allogen
autolog
allogen
patient
infect
preengraft
postengraft
three
patient
consid
immunocompromis
one
follow
reason
uncontrol
hematolog
malign
chemotherapi
month
transplant
prior
steroid
treatment
system
immunosuppress
reduc
tcell
count
hypogammaglobulinemia
detail
clinic
characterist
infect
patient
present
tabl
sixti
four
patient
urti
patient
show
sign
lrti
patient
develop
sever
lrti
defin
icu
treatment
fatal
outcom
thirteen
infect
patient
pneumonia
die
despit
icu
admiss
support
ventil
five
fatal
case
infect
influenza
viru
one
parainfluenza
viru
seven
rsv
oral
tamiflu
ribavirin
given
treatment
patient
immunoglobulin
prepar
patient
palivizumab
administ
signific
differ
regard
demograph
clinic
characterist
influenza
parainfluenza
rsv
infect
patient
furthermor
could
identifi
associ
specif
viru
group
sever
cours
ill
coinfect
detect
patient
total
differ
codetect
pathogen
could
identifi
bacteri
viral
fungal
eg
pseudomona
aeruginosa
bacteremia
cytomegaloviru
reactiv
aspergillu
fumigatu
pneumonia
risk
factor
assess
amongst
infect
patient
show
univari
analysi
endpoint
lrti
uncontrol
hematolog
diseas
ci
p
presenc
coinfect
ci
p
prior
steroid
therapi
ci
p
signific
risk
factor
trend
seen
sever
leukopenia
ie
leukocyt
day
ci
p
regard
endpoint
sever
lrti
presenc
coinfect
ci
p
signific
risk
factor
trend
seen
uncontrol
hematolog
diseas
ci
p
multivari
analysi
signific
influenc
factor
could
identifi
subset
influenzainfect
patient
parainfluenzainfect
patient
rsvinfect
patient
enough
sampl
materi
avail
phylogenet
analysi
influenza
viru
five
sampl
determin
influenza
six
sampl
influenza
four
sampl
influenza
b
virus
belong
yamagatalineag
phylogenet
analysi
ha
sequenc
reveal
ha
gene
form
seven
genet
group
wherein
group
repres
refer
strain
season
group
virus
cocircul
germani
group
virus
domin
compris
genet
subgroup
identifi
virus
belong
subgroup
n
n
group
n
data
shown
molecular
analysi
virus
show
two
variant
cocircul
germani
season
correspond
genet
group
group
virus
domin
compris
genet
subgroup
detect
virus
belong
group
n
subgroup
n
n
among
identifi
virus
two
ha
sequenc
ident
fig
sinc
season
influenza
b
virus
victoria
yamagatalineag
cocircul
differ
season
preval
northern
hemispher
season
yamagatalineag
preval
virus
divid
group
virus
identifi
byamagatalineag
virus
analys
cluster
group
characteris
ident
ha
sequenc
fig
analyz
parainfluenza
viru
posit
sampl
reveal
type
one
sampl
type
sampl
type
sampl
ident
parainfluenza
type
strain
found
fig
rsv
group
specif
pcr
determin
rsv
rsv
b
infect
patient
sequenc
second
hypervari
region
g
gene
sampl
success
obtain
align
repres
rsv
sequenc
phylogenet
tree
rsv
b
sequenc
shown
fig
respect
major
rsva
strain
n
cluster
strain
previous
assign
novel
genotyp
nucleotid
duplic
follow
strain
cluster
genotyp
fig
two
cluster
identifi
within
genotyp
subgroup
cluster
patient
harbor
ident
rsv
strain
g
gene
sequenc
cluster
compris
patient
anoth
set
ident
g
gene
sequenc
fig
thu
rsv
infect
patient
carri
similar
viru
strain
cluster
first
patient
ie
cluster
cluster
communityacquir
infect
subsequ
follow
patient
nosocomi
infect
signific
differ
regard
sever
outcom
infect
two
cluster
vs
asymptomaticurti
vs
nonsever
lrti
vs
sever
lrti
vs
fatal
outcom
cluster
respect
rsvb
strain
n
cluster
strain
previous
assign
ba
genotyp
nucleotid
duplic
ba
strain
could
differenti
genotyp
ba
ix
x
fig
patient
respiratori
viru
infect
followedup
order
analyz
viral
detect
result
infect
patient
sampl
avail
least
two
consecut
week
n
shown
fig
longterm
viru
detectionfor
day
detect
infect
patient
ie
two
influenza
viru
infect
two
parainfluenza
viru
infect
rsv
infect
tabl
compar
clinic
characterist
patient
without
longterm
viru
detect
reveal
significantli
higher
proport
patient
follow
allogen
transplant
longterm
viru
detect
cohort
vs
patient
p
context
worth
notic
patient
extrem
longterm
viru
detect
day
receiv
allogen
transplant
one
patient
without
allogen
transplant
receiv
autolog
transplant
experienc
graftfailur
longterm
leukopenia
regard
morbid
associ
viral
infect
signific
differ
rate
lrti
develop
patient
without
longterm
viru
detect
vs
p
six
rsvinfect
patient
infect
twelv
week
patient
carri
rsv
genotyp
belong
either
cluster
cluster
extens
prolong
viral
shed
note
group
patient
one
patient
die
still
infect
rsv
one
rsv
infect
patient
lost
followup
howev
patient
prolong
infect
clear
viral
infect
demonstr
neg
followup
sampl
tabl
longterm
rsvinfect
patient
present
median
durat
viral
shed
day
rang
day
tabl
interestingli
longterm
rsv
shed
patient
infect
ident
rsv
g
gene
sequenc
found
phylogenet
genotyp
cluster
patient
diagnos
multipl
myeloma
receiv
autolog
allogen
transplant
persist
infect
day
follow
clearanc
infect
surveil
studi
influenza
viru
parainfluenza
viru
rsv
infect
larg
cohort
patient
hematolog
malign
provid
insight
molecular
epidemiolog
circul
pattern
subtyp
genotyp
respiratori
virus
immunocompromis
adult
combin
preval
durat
clinic
impact
prolong
viral
shed
phylogenet
analysi
reveal
varieti
influenza
influenza
byamagatalineag
parainfluenza
rsv
b
virus
whereof
half
patient
n
infect
rsv
subtyp
furthermor
describ
predomin
newli
describ
rsv
genotyp
strain
rsvinfect
patient
identif
two
distinct
cluster
rsv
strain
consist
nosocomi
spread
respons
signific
proport
observ
infect
uniqu
aspect
analysi
repeatedli
perform
screen
viral
respiratori
infect
identifi
patient
longterm
infect
rsv
median
shed
durat
day
high
preval
longterm
shed
respiratori
virus
immunocompromis
patient
might
increas
risk
nosocomi
spread
infect
taken
account
devis
infect
control
measur
adult
patient
hematolog
disord
stem
cell
recipi
respiratori
virus
import
caus
lifethreaten
pneumonia
associ
substanti
morbid
mortal
broader
screen
respiratori
pathogen
hematopoiet
stem
cell
transplant
hsct
recipi
recommend
sever
expert
group
nearli
half
parainfluenza
infect
patient
develop
lrti
accord
report
nichol
et
al
nine
fatal
case
underw
blood
stem
cell
transplant
three
autolog
six
allogen
although
respiratori
virus
might
caus
fatal
pneumonia
contribut
agent
fatal
outcom
difficult
assess
recent
characterist
find
chest
ct
scan
begin
rsv
pneumonia
nodul
treeinbud
sign
often
combin
bronchial
wall
thicken
describ
pathognomon
systemat
analysi
risk
factor
special
cohort
patient
reveal
hypogammaglobulinemia
signific
risk
factor
rsvassoci
morbid
mortal
wherea
treatment
oral
ribavirin
might
provid
protect
effect
progress
rsv
infect
urti
lrti
associ
increas
risk
death
patient
result
case
fatal
rate
among
patient
hematolog
disord
studi
milano
et
al
morbid
mortal
rel
low
hsct
patient
infect
either
rhinoviru
coronaviru
asymptomat
detect
common
molecular
character
respiratori
virus
potenti
aid
identif
infect
chain
studi
cohort
nearli
half
patient
viral
respiratori
infect
infect
influenza
viru
parainfluenza
viru
repres
broad
spectrum
differ
strain
type
similar
result
infect
influenza
parainfluenza
viru
infect
among
patient
haematolog
disord
report
earlier
regard
identifi
influenza
infect
immunocompromis
patient
group
influenza
b
virus
detect
similar
preval
cocircul
influenza
viru
typessubtyp
season
report
nation
influenza
surveil
system
germani
phylogenet
analysi
reveal
preval
proven
influenza
variant
influenza
blineag
test
patient
specimen
match
report
nation
european
influenza
surveil
system
therefor
variant
identifi
populationbas
surveil
within
studi
cohort
differ
variant
caus
mild
sever
clinic
case
could
detect
sever
nosocomi
infect
immunocompromis
patient
describ
present
studi
ident
influenza
influenza
byamagatalineag
ha
sequenc
could
give
indic
nosocomi
transmiss
immunocompromis
patient
character
longer
viral
shed
cours
influenza
viru
infect
longer
time
viral
shed
patient
might
favour
nosocomi
infect
chain
sever
lineag
rsv
within
group
b
cocircul
simultan
popul
rel
proport
may
differ
epidem
although
group
virus
tend
predomin
sequenc
variabl
region
g
protein
gene
wide
use
subdivid
two
subtyp
genotyp
facilit
differenti
rsv
isol
peret
al
establish
classif
differ
genotyp
base
analysi
variabl
rsv
g
gene
date
rsva
genotyp
rsvb
genotyp
baxi
baxii
thb
establish
base
phylogenet
analysi
nucleotid
sequenc
studi
rsv
strain
show
accumul
amino
acid
chang
year
suggest
antigen
driftbas
immunitymedi
select
european
pattern
season
activ
rsv
usual
altern
regular
biennial
rhythm
earli
season
strong
rsv
activ
follow
weaker
late
season
season
viral
acut
respiratori
infect
influenc
meteorolog
condit
describ
previous
vast
major
identifi
rsva
strain
cluster
strain
recent
assign
novel
genotyp
nucleotid
duplic
first
describ
eshaghi
et
al
ontario
canada
germani
circul
genotyp
report
first
time
winter
line
anoth
studi
europ
studi
report
predomin
genotyp
rsv
epidem
season
suggest
rapid
spread
emerg
rsv
strain
two
distinct
phylogenet
cluster
identifi
within
genotyp
subgroup
fifti
percent
rsv
infect
patient
carri
similar
viru
strain
rsvb
strain
cluster
strain
previous
assign
ba
genotyp
nucleotid
duplic
rsv
lineag
similar
strain
patient
simultan
circul
germani
winter
children
line
gradual
spread
ba
genotyp
make
domin
circul
rsvb
genotyp
today
might
result
shift
predomin
genotyp
increas
number
report
across
world
describ
novel
genotyp
follow
season
show
full
impact
evolut
rsva
nucleotid
duplic
genotyp
seem
benefici
viru
novel
strain
show
improv
abil
evad
previous
induc
immun
popul
suggest
immuneescap
strategi
sever
rsv
outbreak
among
hospit
hematolog
patient
report
past
one
studi
involv
post
bone
marrow
transplant
patient
found
nosocomi
infect
rsv
occur
almost
half
patient
ward
nosocomi
transmiss
might
reduc
enhanc
infect
control
program
presenc
two
distinct
cluster
point
nosocomi
transmiss
detect
one
week
later
admiss
mean
incub
period
respiratori
viru
infect
immunocompet
patient
state
four
day
vari
two
eight
day
howev
persist
viral
shed
receiv
littl
attent
immunocompromis
patient
import
observ
studi
prolong
viral
shed
henc
carrier
statu
patient
affect
longterm
viral
shed
day
detect
patient
patient
cohort
mostli
associ
rsv
seventeen
patient
prolong
viral
shed
transplant
patient
patient
allogen
transplant
find
line
recent
studi
heidelberg
major
patient
respiratori
viral
shed
four
week
allogen
transplant
recipi
accord
khanna
et
al
durat
viral
shed
associ
immunosuppress
rsv
subtyp
treatment
regimen
sinc
patient
shed
long
time
seem
prudent
assum
patient
remain
posit
durat
hospit
stay
find
confirm
previou
report
prolong
shed
among
immunocompromis
patient
shed
hematolog
patient
report
week
howev
first
time
rsv
median
shed
durat
long
week
report
recent
milano
et
al
report
prolong
viral
shed
hematopoiet
stem
cell
transplant
recipi
median
durat
viral
shed
rhinoviru
coronaviru
five
week
four
week
respect
prolong
shed
three
month
observ
patient
nosocomi
transmiss
seem
respons
signific
proport
infect
observ
cohort
immunocompromis
patient
one
might
specul
chain
infect
consist
limit
number
viral
strain
introduc
commun
hospit
patient
may
visitor
staff
spread
nosocomi
facilit
prolong
viral
shed
immunocompromis
host
avoid
selfreinforc
circl
earli
detect
isol
infect
patient
well
rigor
hygien
measur
key
import
infect
control
measur
includ
systemat
screen
patient
take
account
incub
period
test
contact
patient
regular
retest
posit
patient
assess
prolong
viral
shed
well
isol
possibl
infect
patient
influenza
prevent
vaccin
recommend
highrisk
popul
immunosuppress
patient
patient
chronic
medic
condit
vaccin
parainfluenza
rsv
licens
yet
newli
develop
vaccin
parainfluenza
viru
immunogen
welltoler
seroneg
young
children
develop
vaccin
could
prevent
rsvrelat
pneumonia
adult
induct
neutral
antibodi
rsv
vaccin
may
potenti
reduc
diseas
sever
adult
popul
new
strategi
rnai
therapeut
shown
exert
potent
antivir
effect
influenza
parainfluenza
rsv
vitro
vivo
molecular
epidemiolog
studi
virus
provid
use
inform
develop
global
effect
vaccin
studi
subject
sever
limit
studi
popul
heterogen
group
regard
varieti
aspect
patient
sampl
obtain
base
routin
screen
respiratori
virus
initi
patient
screen
respiratori
virus
due
clinic
manifest
respiratori
symptom
wherea
later
screen
escal
weekli
screen
patient
regardless
clinic
symptom
addit
mix
cohort
inpati
outpati
includ
studi
regard
treatment
viral
infect
nearli
influenzainfect
patient
receiv
oseltamivir
howev
therapi
immunoglobulin
prepar
ribavirin
option
rsv
infect
patient
given
mainli
discret
attend
physician
final
nontranspl
transplant
patient
includ
accord
ecil
guidelin
panel
test
virus
restrict
influenza
viru
parainfluenza
viru
respiratori
syncyti
viru
virus
eg
metapneumoviru
recommend
ecil
first
line
test
patient
test
perform
conclus
immunocompromis
haematolog
patient
screen
presenc
influenza
viru
parainfluenza
viru
rsv
test
posit
one
three
respiratori
virus
rsv
account
half
detect
infect
newli
emerg
rsv
genotyp
predomin
studi
cohort
global
spread
progress
diversif
strain
sever
lineag
resembl
evolut
rsvb
ba
genotyp
molecular
investig
need
understand
possibl
immunolog
biolog
caus
improv
viral
fit
genotyp
contain
duplic
region
g
gene
line
emerg
ba
genotyp
hypothes
genotyp
could
spread
similar
way
sever
lineag
might
subdivid
genotyp
distinct
phylogenet
cluster
genotyp
rsv
strain
ident
ha
sequenc
influenza
virus
identifi
patient
might
also
indic
nosocomi
transmiss
prolong
viru
shed
observ
especi
patient
rsv
infect
follow
allogen
transplant
might
facilit
nosocomi
spread
pose
major
challeng
infect
control
manag
hospit
set
immunocompromis
patient
taken
account
devis
infect
control
measur
